Since the beginning of the pandemic, SARS-CoV-2 has been suspected of causing chronic fatigue syndrome (ME/CFS). A well-controlled cohort study conducted by a group of researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) has now shown that in the subset of patients who suffer from fatigue and exertion intolerance after mild-COVID-19, around half of patients meet the diagnostic criteria for ME/CFS.
Their findings also describe differences between post-COVID ME/CFS patients and ME/CFS patients in the correlation between hand grip strength and inflammatory biomarkers. This may indicate differences in underlying mechanisms. The researchers’ findings have been published in Nature Communications.
In this webinar, Prof. Dr. Carmen Scheibenbogen (Acting Director of Charité’s Institute of Medical Immunology on Campus Virchow-Klinikum and Solve M.E. Ramsay Research Grant awardee) will discuss the findings of this study, and how the new findings may help researchers to develop specific treatments for post-Covid ME/CFS and ME/CFS.